Form 8-K - Current report:
SEC Accession No. 0000950170-21-000334
Filing Date
2021-06-10
Accepted
2021-06-10 08:35:51
Documents
17
Period of Report
2021-06-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20210610.htm   iXBRL 8-K 44792
2 EX-99.1 rare-20210610ex99_1.htm EX-99.1 37341
3 GRAPHIC img167056165_1.jpg GRAPHIC 25640
4 GRAPHIC img167056165_2.jpg GRAPHIC 375412
5 GRAPHIC img167056165_0.jpg GRAPHIC 375412
6 GRAPHIC img167056165_3.jpg GRAPHIC 25640
  Complete submission text file 0000950170-21-000334.txt   1295905

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20210610_pre.xml EX-101.PRE 9595
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20210610_lab.xml EX-101.LAB 12936
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20210610.xsd EX-101.SCH 2447
10 EXTRACTED XBRL INSTANCE DOCUMENT rare-20210610_htm.xml XML 4522
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 211006977
SIC: 2834 Pharmaceutical Preparations